Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Saori Mishima(Shinshu University Hospital), Kohei Shitara(National Cancer Center Hospital East)

Journal for ImmunoTherapy of Cancer

January 31, 2019

10.1186/s40425-019-0514-3

Cited by 153

Related Papers

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

|Cancer Cell|2022|828

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

|Nature Immunology|2020|810

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

|The Lancet|2023|701

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

|Nature|2021|687